Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if azacitidine, combined with Best Supportive Care
(BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a
different doses and dosing schedules.